Evaluating the prevalence of polyglutamine repeat expansions in amyotrophic lateral sclerosis.
case_control · Level III
Where this comes from
- Record sourced from PubMed, PMID 21562248.
- Also identified by DOI 10.1212/WNL.0b013e31821f4447 and PMC identifier 3111240.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Given the recent finding of an association between intermediate-length polyglutamine (polyQ) expansions in ataxin 2 and amyotrophic lateral sclerosis (ALS), we sought to determine whether expansions in other polyQ disease genes were associated with ALS. We assessed the polyQ lengths of ataxin 1, ataxin 3, ataxin 6, ataxin 7, TBP, atrophin 1, and huntingtin in several hundred patients with sporadic ALS and healthy controls. Other than ataxin 2, we did not identify a significant association with the other polyQ genes and ALS. These data indicate that the effects of ataxin 2 polyQ expansions on ALS risk are likely to be rooted in the biology of ataxin 2 or ataxin 2-specific interactions, rather than the presence of an expanded polyQ repeat per se. These findings have important consequences for understanding the role of ataxin 2 in ALS pathogenesis and provide a framework for future mechanistic studies.
Medical subject headings
- Amyotrophic Lateral Sclerosis
- DNA Repeat Expansion
- Peptides